Table 1 Patient characteristics
From: Outcomes in stage IIA versus stage IIB/III in the PALLAS trial [ABCSG-42/AFT-05/PrE0109/BIG-14-13])
Variable | Stage IIA (N = 1,010 patients randomized [intent to treat]) | Stage IIB/III (N = 4,728 patients randomized [intent to treat]) | ||
|---|---|---|---|---|
Palbociclib + Endocrine therapy (N = 503) | Endocrine therapy (N = 507) | Palbociclib + Endocrine therapy (N = 2,371) | Endocrine therapy (N = 2,357) | |
Age, Years (median, range) | 55 (29–84) | 53 (30–85) | 51 (25–90) | 51 (22–85) |
Sex (at birth) | ||||
Female | 500 (99.4%) | 505 (99.6%) | 2357 (99.4%) | 2341 (99.3%) |
Male | 3 (0.6%) | 2 (0.4%) | 14 (0.6%) | 16 (0.7%) |
Menopausal status | ||||
Postmenopausal | 306 (60.8%) | 288 (56.8%) | 1250 (52.7%) | 1241 (52.7%) |
Pre/Perimenopausal | 194 (38.6%) | 216 (42.6%) | 1106 (46.6%) | 1100 (46.7%) |
Unknown/male patient | 3 (0.6%) | 3 (0.6%) | 15 (0.6%) | 16 (0.7%) |
Histologic grade | ||||
Grade 1/Grade 2 | 346 (68.8%) | 364 (71.8%) | 1574 (66.4%) | 1596 (67.7%) |
Grade 3 | 145 (28.8%) | 127 (25.0%) | 690 (29.1%) | 640 (27.2%) |
Unknown | 12 (2.4%) | 16 (3.2%) | 107 (4.5) | 121 (5.1%) |
Prior chemotherapy | 282 (56.1%) | 279 (55.0%) | 4,180 (88·4%) | |
Clinical risk T/N stage | ||||
T1/N1 | 254 (50.5%) | 250 (49.3%) | – | – |
T2/N0 | 249 (49.5%) | 257 (50.7%) | – | – |